康方生物放量跌超12.5% 依沃西新披露HR值数据低于市场预期

金吾资讯
28 Apr

金吾财讯 | 康方生物(09926)股价放量大跌,午后未见明显起色,截至发稿,报86.5港元,跌幅12.54%,成交额44亿港元。康方生物披露的依沃西(ivonescimab)临床数据中,总生存期(OS)风险比(HR)为0.777,低于市场预期。该数值表明,依沃西相比对照药物帕博利珠单抗(K药)将患者死亡风险降低了22.3%。不过,尽管HR值优于临床意义阈值(通常为0.8),但试验预设的统计学...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10